Ovarian carcinosarcoma cancer is the most lethal form of gynecological malignancy, but the pathogenesis and biological function for this ovarian cancer remain unknown. We establishment the transgenic mouse model of K-ras G12D p53 loxP/loxP and found that K-ras mutation and p53 deletion within the ovarian surface epithelium gave rise to ovarian lesions with a hyperproliferation and endometrioid glandular morphology. Furthermore, double mutant ovaries formed ovarian carcinosarcomas that were high grade and poorly differentiated. Induction was widely metastatic and spread to abdominal organs including liver, spleen, and kidney at 4 wk. We also confirmed the role of K-ras G12D in ovarian cancer cell lines MCAS and PA-1 and showed that Kras G12D overexpression strongly induced cell proliferation, migration, and invasion. The ovarian cancer model we developed recapitulates the specific tumor histomorphology and the probable mechanism of malignant transformation in endometriosis.
Introduction
Carcinosarcoma (malignant mixed mesodermal tumor) is a lethal and infrequent gynecological malignancy, which occurs in <1% of ovarian tumors. It has been reported that ovarian carcinosarcoma is most frequent in postmenopausal women 1 and that surface epithelial tumorigenesis is the most common form of ovarian cancer. Incessant ovulation 2 and the gonadotropin hypothesis 3 are the two major theories that have been proposed for the formation of epithelial ovarian cancer. Ovarian carcinosarcomas are heterogeneous and classified by the World Health Organization as endometrioid adenocarcinoma. Based on recent clinicopathological and molecular studies, the main modes and pathways for the formation of ovarian carcinoma are divided into two precursor and molecular genetic alterations, termed Type I and II. 4 Type I tumors include low-grade serous, mucinous, endometrioid, malignant Brenner, and clear cell carcinomas, with low proliferative activity and a 5-year patient survival rate of 55%. 5 Mutations of the genes K-ras and BRAF are frequently detected in Type I tumors, but K-ras is more commonly mutated (35% of all mutations) than is BRAF (30%). 6 The most common mutations in K-ras are in codons 12, 13, and 61; these lead to constitutive activation of RAS, and thereby increase proliferation and malignant transformation. 7, 8 To carry out systematic analysis of mutation pathways, ovarian tumors were established by engineering Kras mutations, individually or in combination, into transgenic mice. Early studies suggested that endogenous K-ras G12D alleles initiate ovarian peritoneal endometriosis and endometriotic-like lesions in transgenic mice, 9 and the G12D mutation of K-ras has been identified as the main mutation in human epithelial malignancies. 6 Previous studies found that the mutations of Kras (5.8%) are also be detected in Type II ovarian tumors. 10 Type II tumors include high-grade serous, malignant mixed mesodermal tumors (carcinosarcomas), and undifferentiated carcinomas, with high proliferative activity and a 5-year patient survival rate of 30%. Mutations in p53 (37% of all tumours) are frequently detected in Type II tumors. 11 p53, the first tumor suppressor gene to be identified, regulates the cell cycle and functions to prevent cancerous cell growth. Many studies have demonstrated that p53 mutations promote the development of cancer and are associated with poor prognosis. 12, 13 In particular, in epithelial ovarian cancer, p53 has a high mutation probability and its mutation influences the development and/or expansion of malignant ovarian tumor cells. 14 Significant progress in the establishment of epithelial ovarian cancer mouse models has been achieved recently, but most concern well-differentiated or undifferentiated cancer. [15] [16] [17] To understand the genetic link between endometriosis and ovarian cancer, we established transgenic mice that carry both the conditional oncogenic K-ras G12D mutation and p53 deletion to induce precursor lesions of ovarian cancer and characterized the poorly differentiated histopathology of preneoplastic epithelium.
Material and Methods
Generation of mice and genotyping 
Cell Lines
Human ovarian cancer cell lines PA-1 (BCRC, Taiwan) and MCAS (JCRB Cell Bank, Japan) were grown in MEM (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies) and 5% Antibiotic-Antimycotic (Life Technologies) and maintained at 378C in a humidified incubator with 5% CO 2 .
Transfection and Plasmid
Human ovarian cancer cells lines were seeded at 80% confluence and transfected with the KRAS G12D plasmid using TurboFect Transfection Reagent (Fermentas, Hanover, MD). At 24 h post-transfection, culture medium was refreshed and biological assays were carried out.
qPCR Assay
Total genomic DNA was isolated from human ovarian cancer cell lines using Trizol (Invitrogen) and PCR-amplified with the primers of mutation KRS G12D (forward, 5'-TTG TGG TAG TTG GAG CTG A-3'; reverse, 5'-TGG CGT AGG CAA GAG TGC C-3'). Quantitative PCR analysis was conducted using the ABI-7500 system (Applied Biosystems, Foster City, CA, USA).
Cell Growth
Cell growth was quantified using the Cell Counting Kit-8 (Sigma). Briefly, 10 lL Cell Counting Kit-8 was added to 100 lL What's new? Significant progress in the establishment of epithelial ovarian cancer mouse models has been achieved recently, but most concern well-differentiated or undifferentiated cancer. To understand the genetic link between endometriosis and ovarian cancer, here the authors established transgenic mice that carry both the conditional oncogenic K-ras G12D mutation and p53 deletion to induce precursor lesions and characterized the poorly differentiated histopathology of preneoplastic epithelium. The LSL-K-ras G12D/1 p53 loxp/loxp ovarian cancer model recapitulates the specific tumor histomorphology and the probable mechanism of malignant transformation in endometriosis and may be used to study the signaling pathways and mechanisms regulated by K-ras and p53 in ovarian cancer.
cell culture media in a 96-well plate and incubated for 2 h in a CO 2 incubator. The optical absorbance was measured at 450 nm for the supernatant fraction of each well using the plate reader.
Wound-Healing Assay
Wounds were made by scraping cells in 6-well plates with a 200-lL pipette tip in a lengthwise stripe. The cells were washed twice with culture medium and the floating cells were removed. Wound closure was measured and recorded by microscopy.
Invasion Assay
Invasion was measured by the transwell cell culture chamber assay (8-lM pores). 20, 21 Cells (5 3 10 5 ) were placed in the upper chamber with serum-free culture medium, and culture medium with 10% FBS was added to the lower chamber. Plates were incubated at 378C for 24 h; the noninvasive cells on the upper chamber surface were gently removed with a cotton swab and the invasive cells in the bottom of the upper chamber were fixed with 4% formaldehyde solution for 15 min and with 
Results

Ovarian bursal injection of AdCre-GFP results in efficient infection of the ovarian surface epithelium
To examine the activation of the mutated genes LSL-Kras G12D/1 and p53 loxP/loxP within the mouse ovarian surface epithelium (OSE), the schedule is shown in (Fig. 1a) . We generated K-ras G12D/1 p53 loxP/loxP mice by crossing animals heterozygous for LSL-K-ras G12D/1 with p53 loxP/loxP mice; the genotype of each progeny mouse was confirmed by PCR using tail biopsy DNA (Fig. 1b) . All mice were synchronized for ovulation and a recombinant adenoviral vector expressing Cre-GFP (AdCre-GFP) protein was injected into the ovaries that enclose the ovary, frozen sections of mouse ovary were obtained 24 h after AdCre-GFP injection. As expected, GFP immunofluorescence was localized to the OSE (Fig. 1c) . Figure 1 and Figure 2a) . Grossly, the tumors were solid and cystic, with the cysts containing soft masses and hemorrhage as well as its surface with well-developed feeding arteries. At 6 weeks after AdCre infection, hematoxylin and eosin staining showed that the OSE of K-ras
1/1 mice displayed simple endometrioid morphology, an epithelial component of endometriosis, whereas the K-ras G12D/1 p53 loxP/loxP mice showed marked hyperplasia (Fig. 2b) . We observed the survival curve for the cohort of AdCreinjected K-ras G12D/1 p53 loxP/loxP , K-ras (Fig. 3a) . We also found that the tumors in the K-ras G12D/1 p53 loxP/loxP mice had diffusely infiltrated and compressed to the abdominal organs including liver, spleen, and kidney (Fig. 3b) A previous study showed that ovarian and peritoneal endometriotic lesions are identifiable at 8 months after AdCre injection in LSL-K-ras G12D mice. 9 In addition, p53 loss has been implicated in endometrioid ovarian tumorigenesis in humans. 15 ,22 Therefore, we tested whether K-ras G12D/1 p53 loxP/loxP double mutants in the mouse model induced ovarian endometriotic-like tumors. We found that K-ras G12D/1 p53 loxP/loxP mice developed simple endometrioid glandular morphology and peritoneal endometriotic lesions as early as 4 weeks after AdCre injection through the ovarian (Fig. 4a) . To further confirm a diagnosis of endometriosis, immunohistochemistry was analyzed in wild-type uterine endometrium and in Kras
loxP/loxP mouse peritoneal endometriotic lesions. The results showed that both uterine endometrium and endometriotic tissue were positive for endometriotic stroma markers (CD10), 23 but not for smooth-muscle actin (SMA) 24 (Fig. 4b) .
Expression of LSL-K-ras G12D/1 and p53 loxP/loxP in mouse OSE causes endometrioid ovarian carcinosarcoma
To further investigate the detail tumor type of endometrioid ovarian cancer, the AdCre-activated recombination of the LSL-K-ras G12D allele and conditional deletion of p53 specifically induced the ovarian tumors, which was analyzed by immunohistochemical study. Immunohistochemical studies showed that both the internal control tissues and the tumors stained strongly for the markers of epithelium (cytokeratin), 25 endometrial stroma (CD10), 23 mesothelium (calretinin), 26 muscle (desmin), 27 and smooth muscle (SMA), 24 but not for the liposarcoma marker, CDK4 28 ( Fig. 5) . These results suggested that the tumors of Kras G12D/1 p53 loxP/loxP mice that tested positive for the expression of cytokeratin, CD10, calretinin, desmin, and SMA were consistent with a diagnosis of ovarian endometriotic-like lesion carcinosarcoma.
To further investigate the role of the oncogene K-ras G12D allele, we analyzed the proliferation, invasion, and wound healing in human ovarian cancer cell lines PA-1 and MCAS. First, we overexpressed K-ras G12D in these cells (Fig. 6a) , and we found that K-ras G12D increased proliferation, invasion, and wound healing in both cell lines (Fig. 6b, c, and d) , which supported an important role for K-ras G12D in these processes in human ovarian cancer cells.
Discussion
Currently, the development and technology of investigative tools for epithelial ovarian cancer are making significant advances through the application of genetically engineered models that use tissue-specific promoters to simulate the disease 16, 29 or viral infections to induce mutations that affect gene expression. 17, 30 Many studies have used the AdCreinjected mouse model to induce ovarian tumorigenesis, including p53 loxP/loxP Rb3 loxP/loxP , PI3KCA H1047R Pten loxP/loxP , and Kras G12D/1 Pten loxP/loxP mice. 9,15,31 Herein, we report the first mouse model of poor-survival gynecological diseases, those of endometrioid carcinosarcomas of the ovary. The activating LSL-K-ras G12D mutation coupled with p53 loss led to development of carcinosarcomas that spread to the abdominal organs including liver, spleen, and kidney. Using the mouse model K-ras G12D/1 p53 loxP/loxP , we found smallsized ovarian tumors at 4 weeks after AdCre induction that displayed rapidly increasing rates of tumor growth. The ovarian tumor was easily transferred to other organs and the subsequent risk of mortality in mice proved extremely high, which are traits similar to the pathological features of carcinosarcoma in ovarian cancer. 32 From our results in several studies in animal models, we found that K-ras G12D mutation in epithelial cells led to hyperproliferative, hyperplastic glands and enhanced tumor formation on the ovary surface. 9, 18, 33, 34 For primary carcinosarcoma, although we found that K-ras mutation rate is much less frequent in ovarian carcinosarcomas compare to uterine carcinosarcomas, 35, 36 we believe that the establishment of ovarian carcinosarcomas platform would be helpful to the future study including clinical drug screening, signaling pathway and other disease platform establishment (uterine, lung and pancreas).
In addition, we observed that only a small percentage of mice with p53 loss showed tumor formation (data not shown). Some studies have pointed out that most p53 single mutant ovaries are normal, whereas only 5-6% have tumor formations that may be identified as leiomyosarcomas or high-grade serous carcinomas. 15, [37] [38] [39] Furthermore, studies demonstrated that AdCre injection of p53 loxP/loxP Rb3 loxP/loxP induces epithelial ovarian tumors in 97% of mice, of which 61% are high-grade serous, 45% are poorly differentiated, and 15% are undifferentiated. 15 Therefore, K-ras G12D/1 p53 loxP/loxP double mutant ovaries formed ovarian carcinosarcomas that were high grade and poorly differentiated. However, our results showed that the ovaries of K-ras G12D/1 p53 loxP/loxP mice displayed marked OSE cell hyperproliferation and simple endometrioid glandular morphology at 4 weeks after AdCre injection. It has been generally considered that endometriosis-associated ovarian cancer has a relationship to endometrioid ovarian and clear cell carcinomas. Although endometriosis-associated ovarian cancer may be related to ovarian carcinosarcoma, there is presently not sufficient evidence to confirm this relationship, and further studies are necessary. Indeed, our results are consistent with the hypothesis that activating K-ras G12D mutation in combination with p53 loss is sufficient to induce cancerous development in the OSE. The pathogenesis of carcinosarcoma is still unclear, and although the immediate effect of chemotherapy is more effective than in other ovarian cancers, the carcinosarcoma often quickly recurs with relatively poor prognosis, 40, 41 and thus there is no clear consensus on treatment strategy. 42 As a result of this study, we have established a mouse model that can be used not only to better understand carcinosarcoma as a disease but also to study the signaling pathways and mechanisms regulated by K-ras and p53 in human ovarian cancer.
As we develop more fundamental knowledge of relevant gene interactions and protein functions, we will undoubtedly improve the design of therapeutic inhibitors for the treatment of carcinosarcoma and optimize conditions for tests of novel preclinical anticancer drugs, prerequisites for more effective clinical diagnosis and/or treatment of human ovarian cancer in the future.
